Nevro to Report Third Quarter 2021 Financial Results

Rhea-AI Summary

Nevro Corp. (NYSE: NVRO) has announced that it will report its third quarter financial results for the period ending September 30, 2021, after market close on November 8, 2021. A conference call will be held on the same day at 1:30 PM PT to discuss these results. Investors can participate by dialing in or accessing a live webcast available on Nevro's website. Nevro specializes in innovative medical devices for chronic pain treatment, notably through its proprietary 10 kHz Therapy that has shown significant efficacy in reducing opioids usage among patients.

Positive

• Nevro's proprietary 10 kHz Therapy has proven effective in reducing or eliminating opioids in ≥65% of patients across multiple studies.

Negative

• None.

REDWOOD CITY, Calif., Oct. 11, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company will report its financial results for the third quarter ended September 30, 2021 after the market closes on November 8, 2021.

Management will host a conference call on November 8, 2021 to discuss third quarter 2021 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET.  Investors interested in listening to the call may do so by dialing (866) 324-3683 in the U.S. or +1 (509) 844-0959 internationally, using Conference ID: 8987949. A live webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro's website at www.nevro.com. 

Internet Posting of Information

Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com.  The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain.  Nevro's proprietary 10 kHz Therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies.  The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy. 

SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, HFX, the HFX logo, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investors and Media:
Julie Dewey, IRC
Nevro Corp.
Vice President, Investor Relations & Corp Communications
650-433-3247  |  julie.dewey@nevro.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-to-report-third-quarter-2021-financial-results-301391814.html

SOURCE Nevro Corp.

FAQ

When will Nevro report its third quarter 2021 financial results?

Nevro will report its third quarter 2021 financial results on November 8, 2021.

What time is Nevro's conference call for Q3 2021 results?

The conference call will begin at 1:30 PM PT on November 8, 2021.

How can I access Nevro's Q3 2021 financial results?

Investors can access Nevro's Q3 2021 financial results through a live webcast on the company's website.

What is the significance of Nevro's 10 kHz Therapy?

Nevro's 10 kHz Therapy has shown the ability to reduce or eliminate opioid dependence in over 65% of patients in clinical studies.